Cargando…

Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells

BACKGROUND: Survivin, a member of the family of inhibitor of apoptosis proteins, functions as a key regulator of mitosis and programmed cell death. YM155, a novel molecular targeted agent, suppresses survivin, which is overexpressed in many tumor types. The aim of this study was to determine the ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Yan-Fang, Lu, Jun, Du, Xiao-Juan, Sun, Li-Chao, Zhao, Xuan, Peng, Liang, Cao, Lan, Xiao, Pei-Fang, Pang, Li, Wu, Dong, Wang, Na, Feng, Xing, Li, Yan-Hong, Ni, Jian, Wang, Jian, Pan, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543843/
https://www.ncbi.nlm.nih.gov/pubmed/23267699
http://dx.doi.org/10.1186/1471-2407-12-619
_version_ 1782255707368718336
author Tao, Yan-Fang
Lu, Jun
Du, Xiao-Juan
Sun, Li-Chao
Zhao, Xuan
Peng, Liang
Cao, Lan
Xiao, Pei-Fang
Pang, Li
Wu, Dong
Wang, Na
Feng, Xing
Li, Yan-Hong
Ni, Jian
Wang, Jian
Pan, Jian
author_facet Tao, Yan-Fang
Lu, Jun
Du, Xiao-Juan
Sun, Li-Chao
Zhao, Xuan
Peng, Liang
Cao, Lan
Xiao, Pei-Fang
Pang, Li
Wu, Dong
Wang, Na
Feng, Xing
Li, Yan-Hong
Ni, Jian
Wang, Jian
Pan, Jian
author_sort Tao, Yan-Fang
collection PubMed
description BACKGROUND: Survivin, a member of the family of inhibitor of apoptosis proteins, functions as a key regulator of mitosis and programmed cell death. YM155, a novel molecular targeted agent, suppresses survivin, which is overexpressed in many tumor types. The aim of this study was to determine the antitumor activity of YM155 in SK-NEP-1 cells. METHODS: SK-NEP-1 cell growth in vitro and in vivo was assessed by MTT and nude mice experiments. Annexin V/propidium iodide staining followed by flow cytometric analysis was used to detect apoptosis in cell culture. Then gene expression profile of tumor cells treated with YM155 was analyzed with real-time PCR arrays. We then analyzed the expression data with MEV (Multi Experiment View) cluster software. Datasets representing genes with altered expression profile derived from cluster analyses were imported into the Ingenuity Pathway Analysis tool. RESULTS: YM155 treatment resulted in inhibition of cell proliferation of SK-NEP-1cells in a dose-dependent manner. Annexin V assay, cell cycle, and activation of caspase-3 demonstrates that YM155 induced apoptosis in SK-NEP-1 cells. YM155 significantly inhibited growth of SK-NEP-1 xenografts (YM155 5 mg/kg: 1.45 ± 0.77 cm(3); YM155 10 mg/kg: 0.95 ± 0.55 cm(3)) compared to DMSO group (DMSO: 3.70 ± 2.4 cm(3)) or PBS group cells (PBS: 3.78 ± 2.20 cm(3), ANOVA P < 0.01). YM155 treatment decreased weight of tumors (YM155 5 mg/kg: 1.05 ± 0.24 g; YM155 10 mg/kg: 0.72 ± 0.17 g) compared to DMSO group (DMSO: 2.06 ± 0.38 g) or PBS group cells (PBS: 2.36 ± 0.43 g, ANOVA P < 0.01). Real-time PCR array analysis showed between Test group and control group there are 32 genes significantly up-regulated and 54 genes were significantly down-regulated after YM155 treatment. Ingenuity pathway analysis (IPA) showed cell death was the highest rated network with 65 focus molecules and the significance score of 44. The IPA analysis also groups the differentially expressed genes into biological mechanisms that are related to cell death, cellular function maintenance, cell morphology, carbohydrate metabolism and cellular growth and proliferation. Death receptor signaling (3.87E-19), TNFR1 signaling, induction of apoptosis by HIV1, apoptosis signaling and molecular mechanisms of cancer came out to be the top four most significant pathways. IPA analysis also showed top molecules up-regulated were BBC3, BIRC3, BIRC8, BNIP1, CASP7, CASP9, CD5, CDKN1A, CEBPG and COL4A3, top molecules down-regulated were ZNF443, UTP11L, TP73, TNFSF10, TNFRSF1B, TNFRSF25, TIAF1, STK17A, SST and SPP1, upstream regulator were NR3C1, TP53, dexamethasone , TNF and Akt. CONCLUSIONS: The present study demonstrates that YM155 treatment resulted in apoptosis and inhibition of cell proliferation of SK-NEP-1cells. YM155 had significant role and little side effect in the treatment of SK-NEP-1 xenograft tumors. Real-time PCR array analysis firstly showed expression profile of genes dyes-regulated after YM155 treatment. IPA analysis also represents new molecule mechanism of YM155 treatment, such as NR3C1 and dexamethasone may be new target of YM155. And our results may provide new clues of molecular mechanism of apoptosis induced by YM155.
format Online
Article
Text
id pubmed-3543843
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35438432013-01-14 Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells Tao, Yan-Fang Lu, Jun Du, Xiao-Juan Sun, Li-Chao Zhao, Xuan Peng, Liang Cao, Lan Xiao, Pei-Fang Pang, Li Wu, Dong Wang, Na Feng, Xing Li, Yan-Hong Ni, Jian Wang, Jian Pan, Jian BMC Cancer Research Article BACKGROUND: Survivin, a member of the family of inhibitor of apoptosis proteins, functions as a key regulator of mitosis and programmed cell death. YM155, a novel molecular targeted agent, suppresses survivin, which is overexpressed in many tumor types. The aim of this study was to determine the antitumor activity of YM155 in SK-NEP-1 cells. METHODS: SK-NEP-1 cell growth in vitro and in vivo was assessed by MTT and nude mice experiments. Annexin V/propidium iodide staining followed by flow cytometric analysis was used to detect apoptosis in cell culture. Then gene expression profile of tumor cells treated with YM155 was analyzed with real-time PCR arrays. We then analyzed the expression data with MEV (Multi Experiment View) cluster software. Datasets representing genes with altered expression profile derived from cluster analyses were imported into the Ingenuity Pathway Analysis tool. RESULTS: YM155 treatment resulted in inhibition of cell proliferation of SK-NEP-1cells in a dose-dependent manner. Annexin V assay, cell cycle, and activation of caspase-3 demonstrates that YM155 induced apoptosis in SK-NEP-1 cells. YM155 significantly inhibited growth of SK-NEP-1 xenografts (YM155 5 mg/kg: 1.45 ± 0.77 cm(3); YM155 10 mg/kg: 0.95 ± 0.55 cm(3)) compared to DMSO group (DMSO: 3.70 ± 2.4 cm(3)) or PBS group cells (PBS: 3.78 ± 2.20 cm(3), ANOVA P < 0.01). YM155 treatment decreased weight of tumors (YM155 5 mg/kg: 1.05 ± 0.24 g; YM155 10 mg/kg: 0.72 ± 0.17 g) compared to DMSO group (DMSO: 2.06 ± 0.38 g) or PBS group cells (PBS: 2.36 ± 0.43 g, ANOVA P < 0.01). Real-time PCR array analysis showed between Test group and control group there are 32 genes significantly up-regulated and 54 genes were significantly down-regulated after YM155 treatment. Ingenuity pathway analysis (IPA) showed cell death was the highest rated network with 65 focus molecules and the significance score of 44. The IPA analysis also groups the differentially expressed genes into biological mechanisms that are related to cell death, cellular function maintenance, cell morphology, carbohydrate metabolism and cellular growth and proliferation. Death receptor signaling (3.87E-19), TNFR1 signaling, induction of apoptosis by HIV1, apoptosis signaling and molecular mechanisms of cancer came out to be the top four most significant pathways. IPA analysis also showed top molecules up-regulated were BBC3, BIRC3, BIRC8, BNIP1, CASP7, CASP9, CD5, CDKN1A, CEBPG and COL4A3, top molecules down-regulated were ZNF443, UTP11L, TP73, TNFSF10, TNFRSF1B, TNFRSF25, TIAF1, STK17A, SST and SPP1, upstream regulator were NR3C1, TP53, dexamethasone , TNF and Akt. CONCLUSIONS: The present study demonstrates that YM155 treatment resulted in apoptosis and inhibition of cell proliferation of SK-NEP-1cells. YM155 had significant role and little side effect in the treatment of SK-NEP-1 xenograft tumors. Real-time PCR array analysis firstly showed expression profile of genes dyes-regulated after YM155 treatment. IPA analysis also represents new molecule mechanism of YM155 treatment, such as NR3C1 and dexamethasone may be new target of YM155. And our results may provide new clues of molecular mechanism of apoptosis induced by YM155. BioMed Central 2012-12-26 /pmc/articles/PMC3543843/ /pubmed/23267699 http://dx.doi.org/10.1186/1471-2407-12-619 Text en Copyright ©2012 Tao et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tao, Yan-Fang
Lu, Jun
Du, Xiao-Juan
Sun, Li-Chao
Zhao, Xuan
Peng, Liang
Cao, Lan
Xiao, Pei-Fang
Pang, Li
Wu, Dong
Wang, Na
Feng, Xing
Li, Yan-Hong
Ni, Jian
Wang, Jian
Pan, Jian
Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
title Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
title_full Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
title_fullStr Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
title_full_unstemmed Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
title_short Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
title_sort survivin selective inhibitor ym155 induce apoptosis in sk-nep-1 wilms tumor cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543843/
https://www.ncbi.nlm.nih.gov/pubmed/23267699
http://dx.doi.org/10.1186/1471-2407-12-619
work_keys_str_mv AT taoyanfang survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT lujun survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT duxiaojuan survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT sunlichao survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT zhaoxuan survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT pengliang survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT caolan survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT xiaopeifang survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT pangli survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT wudong survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT wangna survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT fengxing survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT liyanhong survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT nijian survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT wangjian survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells
AT panjian survivinselectiveinhibitorym155induceapoptosisinsknep1wilmstumorcells